Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Chinese Subjects with Active SLE
NCT04060888Phase 3Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of ustekinumab in systemic lupus erythematosus (SLE), sponsored by Janssen Pharmaceutical. Planned start Jul 2020; status: withdrawn.
02
Drugs
ustekinumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04060888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04060888.